Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Crobenetine in Healthy Men
NCT02268136Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 1999
- Primary completion
- Dec 1999
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, single-blind trial in ischemic stroke and pain comparing Crobenetine with Placebo (2 arms). Primary endpoints: Number of subjects with clinically relevant changes in vital signs up to 8 days, Number of subjects with adverse events up to 8 days and 3 more. Started Apr 1999; status: terminated.
02
Drugs
crobenetine
03
Conditions
ischemic strokepain
Beyond the preview
Go deeper on NCT02268136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02268136.